Pretomanid

Monitor for hepatotoxicity; if new or worsening liver dysfunction occurs, test for viral hepatitides and discontinue other hepatotoxic medications. Interrupt if aminotransferase elevations are >8×ULN, or >5×ULN and persist over 2wks, or if accompanied by total bilirubin elevation >2×ULN. Myelosuppression. Monitor LFTs, CBCs at baseline, at 2wks, then monthly during treatment and as needed. Decrease or interrupt linezolid dosing if significant myelosuppression develops or worsens. History of Torsade de Pointes. Congenital long QT syndrome. Ongoing hypothyroidism or bradyarrhythmia. Uncompensated heart failure. Obtain ECG prior to initiation, and at least 2,12, and 24 weeks after starting treatment. Obtain serum potassium, calcium, and magnesium at baseline; correct if abnormal. Monitor electrolytes if QT prolongation is detected. Discontinue combination regimen if significant ventricular arrhythmia develops or a QTcF interval >500ms. Monitor visual function; if impairment occurs, interrupt linezolid dosing and perform ophthalmic evaluation. Pregnancy. Nursing mothers.